VC-backed Xenon Pharmaceuticals files for a $52 million IPO: report

Xenon Pharmaceuticals Inc, a Canadian genetic therapy discovery platform, recently filed for an initial public offering with the U.S. Securities and Exchange Commission, reports Renaissance Capital LLC. The company, which is based in Burnaby, British Columbia, seeks to raise US$52 million through a listing on NASDAQ. It has received funding from a mix of Canadian and U.S. venture capital firms since 2000.

CanadaNorth AmericaBriefs